HRT, osteoporosis and regulatory authorities Quis custodiet ipsos custodes?

John C. Stevenson, Martin Birkhäuser, Mark Brincat, Henry Burger, Claus Christiansen, Richard Farmer, John Christopher G. Gallagher, Marco Gambacciani, Andrea R. Genazzani, Ulysse J. Gaspard, Peyman Hadji, Peter Kenemans, Michael Kleerekoper, Robert Lindsay, Jo Marsden, Alfred O. Mueck, Santiago Palacios, Amos Pines, Göran Samsioe, Hermann P G Schneider & 4 others Leon Speroff, John W W Studd, David Sturdee, Malcolm I. Whitehead

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

HRT has been widely used for the relief of menopausal symptoms and the prevention and treatment of post-menopausal osteoporosis. However, following the publication of the Women's Health Initiative (WHI) and the Million Women Study (MWS), regulatory authorities issued an urgent safety restriction on HRT use in preventing post-menopausal osteoporosis, recommending that it now be considered a second-line treatment. Are such recommendations justified? Treatments for osteoporosis, in women with increased future risk for fractures but who have not yet developed the disease, should prevent all types of osteoporotic fractures. Of the available therapies, none other than HRT has been clearly demonstrated to prevent hip fractures in such women. Thus, HRT should be recommended as first-line treatment for osteoporosis prevention. Potential risks of HRT, such as increased development of breast cancer and increased thromboembolism, have long been known. The WHI showed risks in less than 0.3% of women studied, and the MWS appears to have overestimated the risk of breast cancer. Thus, no new safety issues have been identified, and the regulatory authorities may have misinterpreted the data from these recent studies. When given for the correct indications, HRT is of major benefit to many women.

Original languageEnglish
Pages (from-to)1668-1671
Number of pages4
JournalHuman Reproduction
Volume21
Issue number7
DOIs
StatePublished - Jul 2006

Fingerprint

Osteoporosis
Postmenopausal Osteoporosis
Women's Health
Breast Neoplasms
Therapeutics
Safety
Osteoporotic Fractures
Thromboembolism
Hip Fractures
Publications

All Science Journal Classification (ASJC) codes

  • Physiology
  • Developmental Biology
  • Obstetrics and Gynecology
  • Reproductive Medicine

Cite this

Stevenson, J. C., Birkhäuser, M., Brincat, M., Burger, H., Christiansen, C., Farmer, R., ... Whitehead, M. I. (2006). HRT, osteoporosis and regulatory authorities Quis custodiet ipsos custodes? Human Reproduction, 21(7), 1668-1671. https://doi.org/10.1093/humrep/del043

HRT, osteoporosis and regulatory authorities Quis custodiet ipsos custodes? / Stevenson, John C.; Birkhäuser, Martin; Brincat, Mark; Burger, Henry; Christiansen, Claus; Farmer, Richard; Gallagher, John Christopher G.; Gambacciani, Marco; Genazzani, Andrea R.; Gaspard, Ulysse J.; Hadji, Peyman; Kenemans, Peter; Kleerekoper, Michael; Lindsay, Robert; Marsden, Jo; Mueck, Alfred O.; Palacios, Santiago; Pines, Amos; Samsioe, Göran; Schneider, Hermann P G; Speroff, Leon; Studd, John W W; Sturdee, David; Whitehead, Malcolm I.

In: Human Reproduction, Vol. 21, No. 7, 07.2006, p. 1668-1671.

Research output: Contribution to journalArticle

Stevenson, JC, Birkhäuser, M, Brincat, M, Burger, H, Christiansen, C, Farmer, R, Gallagher, JCG, Gambacciani, M, Genazzani, AR, Gaspard, UJ, Hadji, P, Kenemans, P, Kleerekoper, M, Lindsay, R, Marsden, J, Mueck, AO, Palacios, S, Pines, A, Samsioe, G, Schneider, HPG, Speroff, L, Studd, JWW, Sturdee, D & Whitehead, MI 2006, 'HRT, osteoporosis and regulatory authorities Quis custodiet ipsos custodes?', Human Reproduction, vol. 21, no. 7, pp. 1668-1671. https://doi.org/10.1093/humrep/del043
Stevenson JC, Birkhäuser M, Brincat M, Burger H, Christiansen C, Farmer R et al. HRT, osteoporosis and regulatory authorities Quis custodiet ipsos custodes? Human Reproduction. 2006 Jul;21(7):1668-1671. https://doi.org/10.1093/humrep/del043
Stevenson, John C. ; Birkhäuser, Martin ; Brincat, Mark ; Burger, Henry ; Christiansen, Claus ; Farmer, Richard ; Gallagher, John Christopher G. ; Gambacciani, Marco ; Genazzani, Andrea R. ; Gaspard, Ulysse J. ; Hadji, Peyman ; Kenemans, Peter ; Kleerekoper, Michael ; Lindsay, Robert ; Marsden, Jo ; Mueck, Alfred O. ; Palacios, Santiago ; Pines, Amos ; Samsioe, Göran ; Schneider, Hermann P G ; Speroff, Leon ; Studd, John W W ; Sturdee, David ; Whitehead, Malcolm I. / HRT, osteoporosis and regulatory authorities Quis custodiet ipsos custodes?. In: Human Reproduction. 2006 ; Vol. 21, No. 7. pp. 1668-1671.
@article{c63f1d5b85f0444f8bffb584b7357ced,
title = "HRT, osteoporosis and regulatory authorities Quis custodiet ipsos custodes?",
abstract = "HRT has been widely used for the relief of menopausal symptoms and the prevention and treatment of post-menopausal osteoporosis. However, following the publication of the Women's Health Initiative (WHI) and the Million Women Study (MWS), regulatory authorities issued an urgent safety restriction on HRT use in preventing post-menopausal osteoporosis, recommending that it now be considered a second-line treatment. Are such recommendations justified? Treatments for osteoporosis, in women with increased future risk for fractures but who have not yet developed the disease, should prevent all types of osteoporotic fractures. Of the available therapies, none other than HRT has been clearly demonstrated to prevent hip fractures in such women. Thus, HRT should be recommended as first-line treatment for osteoporosis prevention. Potential risks of HRT, such as increased development of breast cancer and increased thromboembolism, have long been known. The WHI showed risks in less than 0.3{\%} of women studied, and the MWS appears to have overestimated the risk of breast cancer. Thus, no new safety issues have been identified, and the regulatory authorities may have misinterpreted the data from these recent studies. When given for the correct indications, HRT is of major benefit to many women.",
author = "Stevenson, {John C.} and Martin Birkh{\"a}user and Mark Brincat and Henry Burger and Claus Christiansen and Richard Farmer and Gallagher, {John Christopher G.} and Marco Gambacciani and Genazzani, {Andrea R.} and Gaspard, {Ulysse J.} and Peyman Hadji and Peter Kenemans and Michael Kleerekoper and Robert Lindsay and Jo Marsden and Mueck, {Alfred O.} and Santiago Palacios and Amos Pines and G{\"o}ran Samsioe and Schneider, {Hermann P G} and Leon Speroff and Studd, {John W W} and David Sturdee and Whitehead, {Malcolm I.}",
year = "2006",
month = "7",
doi = "10.1093/humrep/del043",
language = "English",
volume = "21",
pages = "1668--1671",
journal = "Human Reproduction",
issn = "0268-1161",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - HRT, osteoporosis and regulatory authorities Quis custodiet ipsos custodes?

AU - Stevenson, John C.

AU - Birkhäuser, Martin

AU - Brincat, Mark

AU - Burger, Henry

AU - Christiansen, Claus

AU - Farmer, Richard

AU - Gallagher, John Christopher G.

AU - Gambacciani, Marco

AU - Genazzani, Andrea R.

AU - Gaspard, Ulysse J.

AU - Hadji, Peyman

AU - Kenemans, Peter

AU - Kleerekoper, Michael

AU - Lindsay, Robert

AU - Marsden, Jo

AU - Mueck, Alfred O.

AU - Palacios, Santiago

AU - Pines, Amos

AU - Samsioe, Göran

AU - Schneider, Hermann P G

AU - Speroff, Leon

AU - Studd, John W W

AU - Sturdee, David

AU - Whitehead, Malcolm I.

PY - 2006/7

Y1 - 2006/7

N2 - HRT has been widely used for the relief of menopausal symptoms and the prevention and treatment of post-menopausal osteoporosis. However, following the publication of the Women's Health Initiative (WHI) and the Million Women Study (MWS), regulatory authorities issued an urgent safety restriction on HRT use in preventing post-menopausal osteoporosis, recommending that it now be considered a second-line treatment. Are such recommendations justified? Treatments for osteoporosis, in women with increased future risk for fractures but who have not yet developed the disease, should prevent all types of osteoporotic fractures. Of the available therapies, none other than HRT has been clearly demonstrated to prevent hip fractures in such women. Thus, HRT should be recommended as first-line treatment for osteoporosis prevention. Potential risks of HRT, such as increased development of breast cancer and increased thromboembolism, have long been known. The WHI showed risks in less than 0.3% of women studied, and the MWS appears to have overestimated the risk of breast cancer. Thus, no new safety issues have been identified, and the regulatory authorities may have misinterpreted the data from these recent studies. When given for the correct indications, HRT is of major benefit to many women.

AB - HRT has been widely used for the relief of menopausal symptoms and the prevention and treatment of post-menopausal osteoporosis. However, following the publication of the Women's Health Initiative (WHI) and the Million Women Study (MWS), regulatory authorities issued an urgent safety restriction on HRT use in preventing post-menopausal osteoporosis, recommending that it now be considered a second-line treatment. Are such recommendations justified? Treatments for osteoporosis, in women with increased future risk for fractures but who have not yet developed the disease, should prevent all types of osteoporotic fractures. Of the available therapies, none other than HRT has been clearly demonstrated to prevent hip fractures in such women. Thus, HRT should be recommended as first-line treatment for osteoporosis prevention. Potential risks of HRT, such as increased development of breast cancer and increased thromboembolism, have long been known. The WHI showed risks in less than 0.3% of women studied, and the MWS appears to have overestimated the risk of breast cancer. Thus, no new safety issues have been identified, and the regulatory authorities may have misinterpreted the data from these recent studies. When given for the correct indications, HRT is of major benefit to many women.

UR - http://www.scopus.com/inward/record.url?scp=33745808844&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745808844&partnerID=8YFLogxK

U2 - 10.1093/humrep/del043

DO - 10.1093/humrep/del043

M3 - Article

VL - 21

SP - 1668

EP - 1671

JO - Human Reproduction

JF - Human Reproduction

SN - 0268-1161

IS - 7

ER -